Literature DB >> 35062062

The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy.

Ali Baradaran1, Zahra Asadzadeh2, Nima Hemmat3, Amir Baghbanzadeh2, Mahdi Abdoli Shadbad4, Neda Khosravi2, Afshin Derakhshani5, Hajar Alemohammad2, Mina Afrashteh Nour2, Hossein Safarpour6, Nicola Silvestris7, Oronzo Brunetti8, Behzad Baradaran9.   

Abstract

Tumor-associated macrophages (TAMs) are among the abundant cell populations of the tumor microenvironment (TME), which have pivotal roles in tumor development, chemoresistance, immune evasion, and metastasis. Growing evidence indicates that TAMs and the cross-talk between TAMs and tumoral endothelial cells can substantially contribute to tumor angiogenesis, which is considered a vital process for cancer development. Besides, tumoral endothelial cells can regulate the leukocyte infiltration to the TME in solid cancers and contribute to immune evasion. Therefore, targeting the immunosuppressive TAMs and the cross-talk between them can be a promising strategy for improving anti-tumoral immune responses. This review aims to summarize the biology of TAMs, their recently identified roles in tumor development/angiogenesis, and recent advances in macrophage-based cancer immunotherapy approaches for treating cancers.
Copyright © 2021. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Angiogenesis; Cancer; Endothelial cells; Tumor microenvironment; Tumor-associated macrophages

Mesh:

Substances:

Year:  2021        PMID: 35062062     DOI: 10.1016/j.biopha.2021.112588

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

Review 1.  The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies.

Authors:  Ruixue Bai; Yunong Li; Lingyan Jian; Yuehui Yang; Lin Zhao; Minjie Wei
Journal:  Mol Cancer       Date:  2022-09-08       Impact factor: 41.444

2.  Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment.

Authors:  Xiangxiang Liu; Jian Qin; Junjie Nie; Huiling Sun; Yuqin Pan; Shukui Wang
Journal:  Front Genet       Date:  2022-09-21       Impact factor: 4.772

3.  Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.

Authors:  Domenico Mallardo; Ester Simeone; Vito Vanella; Maria Grazia Vitale; Marco Palla; Luigi Scarpato; Miriam Paone; Teresa De Cristofaro; Valentina Borzillo; Alessio Cortellini; Francesca Sparano; Sandro Pignata; Francesco Fiore; Corrado Caracò; Piera Maiolino; Antonella Petrillo; Ernesta Cavalcanti; Secondo Lastoria; Paolo Muto; Alfredo Budillon; Sarah Warren; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.